HDLForum

register login
  • Skip to content
  • Homesummary
  • About HDL Forum 
  • News 
    • News
    • Meeting reports
    • Forthcoming Meetings
  • Resources 
    • Slides
    • Societies
    • Guidelines
    • Links
    • Glossary
  • Ask the Expert 
    • Viewpoints
    • Roundtable discussion
    • Expert Opinion
  • HDL Essentials 
    • About CETPi Forum
    • About HDL Forum
  • Register 
  • Contact 
Click on the slide!
Click on the slide!
Click on the slide!
Click on the slide!
  • «
  • Click to navigate! 01 Latest News
  • Click to navigate! 02 Viewpoints
  • Click to navigate! 03 Resources
  • Click to navigate! 04 Forthcoming Meetings
  • »
  • Pause
Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

High-Density Lipoprotein Cholesterol (HDL-C)

  • Often referred to as "good cholesterol", HDL scavenges collecting excess atherogenic cholesterol particles which are transported to the liver for excretion
  • Population studies show that HDL-C is an independent risk factor for cardiovascular disease
  • Low HDL-C is common in people with cardiovascular disease, type 2 diabetes and metabolic syndrome
  • Treatments to raise HDL-C are a major focus of scientific and clinical research today

About HDL Forum

  • The only independent source of news and expert analysis specifically focused on HDL-C
  • Peer-reviewed and open access
  • Resources include downloadable powerpoint presentations and continuing education programmes
  • Updated weekly

REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS

What's New

  • Low HDL2 is associated with increased coronary risk
  • HDL: possible anti-calcifying effect in aortic valves?
  • HDL functionality in high-risk patients at LDL goal
  • Emerging therapies: MicroRNAs
  • New insights into ABCA1, reverse cholesterol transport and HDL cholesterol
  • Isolated low HDL-C increases coronary risk

Hot Topic

Managing dyslipidemic patients with the metabolic syndrome - Focus on the HDL-triglyceride axis
A roundtable discussion for HDL Forum held during the European Atherosclerosis Society Congress, 26-29th June, 2011 Gothenburg, Sweden

 


Discussion of critical clinical and scientific questions by key opinion leaders

Outcomes studies with CETP inhibitors - hypothetical discussions

Professor Philip Barter, HDL Forum Editor and Director of The Heart Research Institute, Sydney Australia


Editors

  • Professor Kerry-Anne Rye

    Head of Lipid Research Group
    Read more...


  • Professor Philip Barter

    Director
    Read more...


  • Professor John Chapman

    Director
    Read more...

     


    Click here for the Editorial Board

REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS

 Supported by unrestricted medical
educational grants from

 

 Supporters have no editorial influence
over the content of this website

Unless otherwise indicated, opinions expressed in HDL Forum are those of the contributors.  Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the sponsor, publisher, editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2012 . All rights reserved.



  • Forgot your password?
  • Forgot your username?
  • Create an account